Positive News SentimentPositive NewsNASDAQ:TYRA Tyra Biosciences (TYRA) Stock Price, News & Analysis $31.29 +0.23 (+0.74%) As of 09:32 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Tyra Biosciences Stock (NASDAQ:TYRA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Tyra Biosciences alerts:Sign Up Key Stats Today's Range$31.25▼$31.2550-Day Range$25.42▼$33.7852-Week Range$9.96▼$40.65Volume470 shsAverage Volume919,048 shsMarket Capitalization$1.86 billionP/E RatioN/ADividend YieldN/APrice Target$47.00Consensus RatingModerate Buy Company Overview Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need. The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells. Lead candidates are designed to inhibit key enzymes and signaling pathways implicated in tumor growth and survival. Tyra Biosciences collaborates with academic research centers and employs translational biomarker strategies to streamline clinical development and patient selection. Headquartered in South San Francisco, California, Tyra Biosciences operates with a global outlook, engaging with regulatory authorities and clinical investigators across North America and Europe. The company is led by a team of executives and scientists with extensive experience in oncology drug development, aiming to bring novel targeted therapies from discovery through clinical proof-of-concept.AI Generated. May Contain Errors. Read More Tyra Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks64th Percentile Overall ScoreTYRA MarketRank™: Tyra Biosciences scored higher than 64% of companies evaluated by MarketBeat, and ranked 337th out of 834 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingTyra Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.87, and is based on 1 strong buy rating, 12 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialTyra Biosciences has a consensus price target of $47.00, representing about 50.2% upside from its current price of $31.29.Amount of Analyst CoverageTyra Biosciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Tyra Biosciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Tyra Biosciences are expected to decrease in the coming year, from ($2.68) to ($2.95) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tyra Biosciences is -14.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tyra Biosciences is -14.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTyra Biosciences has a P/B Ratio of 6.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Tyra Biosciences' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted19.08% of the float of Tyra Biosciences has been sold short.Short Interest Ratio / Days to CoverTyra Biosciences has a short interest ratio ("days to cover") of 15.5, which indicates bearish sentiment.Change versus previous monthShort interest in Tyra Biosciences has recently decreased by 16.72%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTyra Biosciences does not currently pay a dividend.Dividend GrowthTyra Biosciences does not have a long track record of dividend growth. News and Social Media3.6 / 5News Sentiment1.73 News SentimentTyra Biosciences has a news sentiment score of 1.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.91 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Tyra Biosciences this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for TYRA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.2 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Tyra Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders12.50% of the stock of Tyra Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions84.14% of the stock of Tyra Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Tyra Biosciences' insider trading history. Receive TYRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tyra Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TYRA Stock News HeadlinesTyra Biosciences (NASDAQ:TYRA) Trading 5% Higher - Time to Buy?July 19, 2026 | americanbankingnews.comIs Tyra Biosciences, Inc. (TYRA) Stock a Biotech Opportunity Ahead of Key SURF302 Trial Data?June 30, 2026 | finance.yahoo.comNevada gold explorer near Kinross district draws attentionGold has surged past $5,300 per ounce, with Goldman Sachs and JPMorgan forecasting $6,000+ by end of 2026. Central banks bought a record 863 tonnes in 2025 alone - and one small-cap explorer in Nevada's Walker Lane Belt may be positioned to benefit. Sitting 18 miles north of Tonopah in the same district that produced over 15 million ounces at Kinross Gold's Round Mountain Mine, this explorer carries historic drill intercepts of 30 meters at 2.5 g/t gold and surface samples exceeding 100 g/t. With a market cap under $15 million and drills ready to turn in H2 2026, the window may be narrow.July 28 at 1:00 AM | Wall Street Logic (Ad)Is Tyra Biosciences, Inc. (TYRA) Stock a Biotech Opportunity Ahead of Key SURF302 Trial Data?June 30, 2026 | finance.yahoo.comNon-muscle Invasive Bladder Cancer Market Dynamics to Shift During the Forecast Period (2026-2036) as Novel Targeted and Gene Therapies Enter Late-Stage Development | DelveInsightJune 23, 2026 | finance.yahoo.comAnalysts Are Bullish on Top Healthcare Stocks: ClearPoint Neuro (CLPT), Tyra Bioscience (TYRA)June 20, 2026 | theglobeandmail.comIs Tyra Biosciences (TYRA) Too Reliant On Dabogratinib Amid Renewed SURF-302 Skepticism?June 12, 2026 | finance.yahoo.comWolfe Research Initiates Peer Perform rating on Tyra Biosciences, Inc. (TYRA)June 1, 2026 | finance.yahoo.comSee More Headlines TYRA Stock Analysis - Frequently Asked Questions How have TYRA shares performed this year? Tyra Biosciences' stock was trading at $26.29 on January 1st, 2026. Since then, TYRA stock has increased by 19.0% and is now trading at $31.29. How were Tyra Biosciences' earnings last quarter? Tyra Biosciences, Inc. (NASDAQ:TYRA) announced its quarterly earnings results on Wednesday, May, 13th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by $0.04. When did Tyra Biosciences IPO? Tyra Biosciences (TYRA) raised $162 million in an IPO on the week of September 13th 2021. The company issued 10,800,000 shares at a price of $14.00-$16.00 per share. Who are Tyra Biosciences' major shareholders? Top institutional investors of Tyra Biosciences include Tema ETFs LLC (0.05%). Insiders that own company stock include Robert J More, Todd Harris, Nina S Kjellson, Daniel Bensen, Gilla Kaplan and Alan Fuhrman. View institutional ownership trends. How do I buy shares of Tyra Biosciences? Shares of TYRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Tyra Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tyra Biosciences investors own include American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC), Waste Connections (WCN), AUO (AUOTY) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings5/13/2026Today7/28/2026Next Earnings (Estimated)8/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 TYRA's financial health is in the Green zone, according to TradeSmith. TYRA has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TYRA CIK1863127 Webwww.tyra.bio Phone619-728-4760FaxN/AEmployees20Year Founded2018Price Target and Rating Average Price Target for Tyra Biosciences$47.00 High Price Target$56.00 Low Price Target$35.00 Potential Upside/Downside+51.3%Consensus RatingModerate Buy Rating Score (0-4)2.87 Research Coverage15 Analysts Profitability EPS (Trailing Twelve Months)($2.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$119.95 million Net MarginsN/A Pretax MarginN/A Return on Equity-42.66% Return on Assets-39.79% Debt Debt-to-Equity RatioN/A Current Ratio20.49 Quick Ratio20.49 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.86 per share Price / Book6.39Miscellaneous Outstanding Shares59,470,000Free Float52,036,000Market Cap$1.85 billion OptionableOptionable Beta0.76 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:TYRA) was last updated on 7/28/2026 by MarketBeat.com Staff. From Our PartnersNevada gold explorer near Kinross district draws attentionGold has surged past $5,300 per ounce, with Goldman Sachs and JPMorgan forecasting $6,000+ by end of 2026. Cen...Wall Street Logic | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredHow the JPMorgan $8,000 Gold Call Exposed the Biggest Mistake in Most Retirement AccountsJPMorgan has raised its 2026 gold forecast to $6,300, with a credible path to $8,000, and now calls gold a cor...Golden Crest Metals | SponsoredA 50-year dollar arrangement just ended - what it means for youIn 1974, Henry Kissinger helped create the U.S.-Saudi Arabia Joint Commission on Economic Cooperation - a litt...Golden Portfolio | SponsoredSpaceX pays a 10X launch penaltySpaceX burns roughly $200,000 in fuel per Falcon 9 launch - about $20 million across 100 missions. One unde...Freedom Financial | Sponsored60 years. Zero competitors.One company has spent 60 years developing an energy source the International Energy Agency estimates at 140 ti...Behind the Markets | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredWhat Elon told his top shareholders in TexasLate last year, Elon Musk gathered top shareholders at Tesla's Texas Gigafactory to unveil a plan to double Am...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tyra Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tyra Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TYRA Stock Alerts